According to the indicator at the base of the advisor Marketmiracle the CLVS stock is accumulating capitals and is ready for an explosion.
Clovis Oncology is one of the best-selling low-cost titles but produces a drug capable of improving the lives of cancer patients worldwide.
Clearly the money devoted to biotech and pharmaceutical companies during the covid...
The Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately
The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data far above the expectations of analysts.
Recently a reverse split...
This company is going to be huge.
It's already passing the Phase 3 ARIEL4 study.
Revenue has been beaten in last quarter report. (although there was a small overestimate for the profit(loss) per share)
The MACD indicator is bouncing back (also the price is pushing through the Moving Averages).
Price is now in the channel (2 thick red dot...
Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company.
· Current Price – $0.0419
· Best Case Scenario PT over 1$
· Market Cap – $11 million
· Debt – 0
Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the...
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need.
After an insider at Mersana Therapeutics bought shares following a May 2020 selloff triggered by an interim data release, the stock rallied over 400% during the next eight months.
+ back-tested the previous AH. looking to re-test current AH and climb to a new AH.
+ The more Saphyrs deployed = More Rev./Earnings = Higher Share Price.
+ 10,000 Deployed Saphyrs GOAL 2021 according to CEO Eric. $14 PT was given based on only 600 Deployed Saphyrs. $14 x 16.666 = $233.33 PT .
+ Cheers to a fun week ahead. It's been a long time coming.
Shorts are doing the loyal investors a favor, they are man-making a solid resistance level to spring board from. When this hits $20, it will happen fast more than likely within hours... Just get in and sun block up... this is a long term play, not a spac, a P&D, or a penny stock... what you are witnessing is magic and it only happens once every decade or so... cheers.
Why SELLAS Life Sciences Is Surging Premarket?
SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine
Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know?
its leading candidate Galinpepimut-S is making its way through Phase 3.
$EXAS is looking strong with a potentially good entrance for a gap up.
BUY signal with 8 confirmations.
Happy Trading, from CJ -- aka the greatest FURU.
To find out more about The Ultimate Stock Indicator on Tradingview, please check my public profile.
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary...
Atara Biotherapeutics , Inc. (Nasdaq: ATRA ), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases
"Atara made significant progress in 2020 and is well-positioned for a strong 2021," said...
Seeing a turn in cancer genetics incorporated... looks juicy.
Triple bottom structure with a recent falling wedge breakout on the overall expanding downward channel.
Each time on the turning point of this major multi year support we saw major impulsive moves shortly after.
Given that the price in time now is at a much lower discount compared to history. I think...
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol.
A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also...